AVR Anteris Technologies Global Cor
$6.14▲ +2.33%
Healthcare
Other
Volume 673.5K
Avg Volume (10D) 1.44M
Key Metrics & Fundamentals
Market Cap
$598.40M
P/E Ratio
–
Div Yield
0.00%
52W Range
3.30 - 11.06
% vs 50 MA
-22.60%
% vs 200 MA
-18.50%
RSI-14
31.8
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.40
Free Cash Flow
-$21.45M
Gross Rev
$1.01M
Gross Profit
$776,000
EBITDA
-$28.11M
COGS
$233,000
Operating Exp
$31.77M
Operating Income
-$31.00M
EBIT
-$31.00M
Pretax Income
-$28.78M
Net Income
-$29.09M
EPS (Diluted)
-0.30
Price & Volume History
Loading chart…
Recent News
Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026
GlobeNewswire · Oct 27, 2026 6:00 AM ET
Anteris Technologies secures German clearance to expand PARADIGM heart valve trial
Proactive · Oct 19, 2026 10:02 PM ET
Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance
GlobeNewswire · Oct 19, 2026 9:12 PM ET
Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
The Fly · Oct 7, 2026 10:00 AM ET
Anteris Technologies appoints Brent Moen as chief financial officer
Proactive · Sep 6, 2026 7:47 PM ET
Anteris to Present at September Healthcare Investor Conferences
GlobeNewswire · Aug 31, 2026 2:45 PM ET
Anteris Technologies Q2 Loss Narrows, Net Sales Rise
MT Newswires · Aug 12, 2026 3:19 AM ET
Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway
Proactive · Aug 11, 2026 7:22 PM ET
Anteris Technologies Announces Results for the Second Quarter of 2026
GlobeNewswire · Aug 11, 2026 7:00 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See AVR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.